Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of ...
Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on Biotech Distilled’s Substack.
AZN's Ultomiris wins FDA priority review for IgAN, backed by late-stage data showing a 43.4% proteinuria reduction versus ...
Wells Fargo analyst Mohit Bansal maintained a Buy rating on Travere Therapeutics yesterday and set a price target of $65.00. Designed for personal research, portfolio monitoring, and AI-assisted ...
EVEREST MED (01952.HK) announced that its wholly owned subsidiary, Everest Medicines (Singapore) Pte. Ltd., as licensor, has ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Healthcare companies balance science, innovation and hope in the pursuit of better diagnostics, treatments and even cures, ...
Detailed price information for Seagate Technology Holdings (STX-Q) from The Globe and Mail including charting and trades.
Investor's Business Daily on MSN
Stock market today: Dow ends higher on Iran deal hopes; SpaceX rockets 19% in debut
Stock Market Today: The Dow Jones index rises Friday on U.S.-Iran peace deal hopes. SpaceX stock jumps on its debut.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results